Medical AI Alliance
← Company Index
Pharma & CDMOKOSDAQ 220100Orphan Drug11 approvals10 trials

FutureChem Co., Ltd.

Official website

Develops the PSMA-targeted prostate cancer diagnostic FC303 and therapeutic FC705 radiopharmaceuticals.

As of 2026-10-11, FutureChem Co., Ltd. has 3 Korean MFDS device approvals, 7 Korean MFDS drug approvals, 25 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2001 and listed on KOSDAQ in 2016, FutureChem is a company specializing in radiopharmaceutical drug development. In 2008 it commercialized the lung cancer diagnostic [18F]FLT and the Parkinson's disease diagnostic Fidewe ([18F]FP-CIT), and obtained marketing approval for Alzaview ([18F]Florapronol), Korea's 29th domestically developed new drug, for Alzheimer's diagnosis; it also holds a pipeline including the prostate cancer diagnostic FC303, brain tumor diagnostic [18F]FMT, cardio-cerebrovascular disease diagnostic [18F]FC505, Alzheimer's diagnostic [18F]FC211, and the PSMA-targeted prostate cancer therapeutics FC705 ([LU-177]FC705, [AC-225]FC705). FC303 has completed domestic trials and is under marketing approval review, completed US Phase 1, and is in Phase 3 trials in Europe and China through overseas partners, while FC705 received a Korean Phase 2 clinical study report in April 2025, is seeking Phase 3 approval, and is in FDA Phase 2a trials in the US.

Products & technology

  • Fidewe ([18F]FP-CIT)Parkinson's disease diagnosis
  • [18F]FLTLung cancer diagnosis
  • Alzaview ([18F]Florapronol)Alzheimer's disease diagnosis
  • FC303Prostate cancer diagnosis
  • FC705 ([LU-177]FC705, [AC-225]FC705)PSMA-targeted prostate cancer treatment

Regulatory approvals

data.go.kr

1 Orphan Drug designations · 2024 / 7 Korean MFDS drug approvals · 2005–2026 / 3 Korean MFDS device approvals · 2004–2005

  • Orphan[177Lu]루도타다이펩2024-07-12
    Orphan Drug designation · in development20240119325
  • MFDS drugProstavue(Florastamin(18F)) injection2026-04-30
    Drug · Prescription · Approval202601314
  • MFDS drug퓨쳐켐에프디지주사액(2-데옥시-2-플루오로-D-글루코스(18F)액)2020-08-21
    Drug · Prescription · Approval202005943
  • MFDS drug알자뷰주사액(플로라프로놀(18F)액)2018-02-02
    Drug · Prescription · Approval201800667
  • MFDS drug피디뷰주사(플루오로프로필씨아이티(18F))2014-11-18
    Drug · Prescription · Approval201405355
  • MFDS drugSubsidiary: 주식회사 퓨쳐켐헬스케어퓨쳐켐소듐플루오라이드F-18주사액Revoked2014-11-07
    Drug · Prescription · Approval201405200
  • MFDS drugSubsidiary: 주식회사 퓨쳐켐헬스케어퓨쳐켐암모니아N13주사액Revoked2014-10-28
    Drug · Prescription · Approval201404987
  • MFDS drugSubsidiary: 주식회사 퓨쳐켐헬스케어메타트레이스에프디지-10(2-데옥시-2-플루오로-D-글루코스(18F))액2005-06-01
    Drug · Prescription · Approval200503741
  • MFDSSubsidiary: 주식회사 퓨쳐켐헬스케어양전자방출전산화단층촬영장치Revoked2005-04-29
    Product approval · Class 3수허 05-378 호
  • MFDSSubsidiary: 주식회사 퓨쳐켐헬스케어양전자방출전산화단층촬영장치Revoked2004-06-14
    Product approval · Class 2수허 04-773 호
  • MFDSSubsidiary: 주식회사 퓨쳐켐헬스케어양전자방출전산화단층촬영장치Revoked2004-03-06
    Product approval · Class 2수허 04-308 호

Clinical trials

data.go.kr

10 MFDS clinical trial authorisations · 2013–2025 (Phase 3 5 · Phase 1 4 · Phase 2 1)

  • Phase 3[177Lu]루도타다이펩2025-09-04

    9 trial sites

  • Phase 3[F-18]Florastamin2024-10-18

    5 trial sites

  • Phase 3[F-18]Florastamin2022-12-26

    22 trial sites

  • Phase 2[177Lu]루도타다이펩2022-05-13

    1 trial site

  • Phase 3[F-18]Florastamin2020-11-30

    10 trial sites

  • Phase 1[177Lu]루도타다이펩2020-05-27

    1 trial site

  • Phase 1[F-18]Florastamin2019-09-23

    1 trial site

  • Phase 1[F-18]Florastamin2019-07-29

    1 trial site

  • Phase 3[18F]FC119S2014-09-05

    1 trial site

  • Phase 1[18F]FC119S2013-07-12

    1 trial site

Global clinical trials

ClinicalTrials.gov · sponsor-matched

R&D and key agreements

Source: DART corporate disclosure

FC303 · 전립선암 진단 · 국내 품목허가신청, 미국임상1상완료, 유럽·중국임상3상진행 · Approved for European (Austria) Phase 3 via overseas partner in May 2021; China Phase 3 also underway via overseas partner

FC705 · PSMA 전립선암 치료 · 국내임상3상승인신청, 미국FDA임상2a상진행 · Received Korean Phase 2 CSR in April 2025; US FDA Phase 1/2a approved May 2022, Phase 1 completed May 2023 (CSR received September), currently in Phase 2a

Key disclosures

KRX KIND via OpenDART
Show 11 more events

Publications

PubMed · affiliation-matched
Show 15 more publications

Patents

KIPRIS · applicant-matched
Show 41 more patents

AI reads

MAA server logs · IP-verified
77
Times AI engines pulled FutureChem Co., Ltd.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

4
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

73
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

14
live 1
Last 7 days
64
live 3
Last 30 days
77
live 4
All time
  • OpenAIChatGPT-Userlive4
  • OpenAIOAI-SearchBot63
  • PerplexityPerplexityBot4
  • GoogleGoogleOther3
  • AnthropicClaudeBot2
  • MicrosoftBingbot1

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 10, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for FutureChem Co., Ltd. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies in the same categoryPharma & CDMO

ILDONG HOLDINGS CO.,LTD100

Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.

Yuyu Pharma, Inc.100

Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.

IL DONG PHARMACEUTICAL CO., LTD.100

Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.

Medy-Tox Inc.99

Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.

GC Biopharma Corp.97

KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.

DAEWON PHARMACEUTICAL CO.,LTD85

KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.

SAMSUNG BIOLOGICS CO.,LTD.85

Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.

GENOLUTION INC.85

Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.

AHN-GOOK PHARMACEUTICAL Co., Ltd.85

Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.

CORESTEMCHEMON Inc.85

Founded in 2003 and listed on KOSDAQ in 2015, Corestem Chemon develops stem cell therapies and provides nonclinical CRO services, including the ALS treatment Neuronata-R.

BIO-FD&C CO.,LTD.85

Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.

HANDOK Inc.85

KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition